SEQSTER has announced the expansion of its partnership with Praxis Precision Medicines to expedite clinical trials in CNS ...

CalciMedica will now evaluate how it can safely progress Auxora’s development in AKI, while finalising plans for a Phase III ...

Jen Lamppa, VP of Commercial Strategy at Inovalon, says that RWD will be held to the same scrutiny as trial data if used in ...

Real-world evidence (RWE) empowers payers and providers to make more informed, cost-effective treatment. Read more here: ...

A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.

BBH has entered a partnership with PhaseWell Research aimed at expanding access to neuropsychiatric clinical trials.

Genespire is looking to take its single-dose gene therapy, GENE202, to the clinic by the end of 2026, where it will be ...

Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap its development.

Ascletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule GLP-1 receptor agonist, intended for treating type 2 diabetes mellitus.

William Blair analysts view Elevidys’ three-year outcome as a win for Sarepta, though they remain sceptical on the readout’s sales impact.

A spokesperson for the US Department of State told Pharmaceutical Technology that the “American people have paid more than enough” to the WHO.

In Phase Ib, BSI-082 will be combined with trastuzumab deruxtecan for HER2-positive solid tumours. Credit: PeopleImages / Shutterstock.com. Biosion has dosed the first patient in an ...